3% Increase In Sales For Sandoz

31 October 1994

Group sales at Sandoz for the first nine months of 1994 amounted to 11.9 billion Swiss francs ($9.5 billion), up only 3% on the like, year-earlier period as a result of the strong appreciation of the Swiss franc. In local currencies the increase amounted to 9%.

The life sciences business segment achieved sales of just over 8 billion francs, ahead 6%, or 12% in local currencies. The other business segment, chemicals and environment, achieved sales of 3.8 billion francs, a decline of 2% when expressed in Swiss franc terms, or a rise of 3% in local currencies.

Nine-Month Sales Breakdown Sales SwFr Local (SwFr mill) Life Sciences 8,066.0 +6% +12% Pharmaceuticals 5,379.0 -2% +4% Nutrition 1,868.0 +43% +50% Seeds 819.0 -2% +5% Chemicals & Environment 3,819.0 -2% +3% Chemicals 1,757.0 -8% -2% Agro 1,131.0 +5% +10% Construction & Environment 931.0 +4% +8% Total 11,885.0 +3% +9%

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight